Eli Lilly’s crop of new products propelled the ... for the firm was likely the resilience of its diabetes blockbuster Trulicity. Trulicity (dulaglutide) grew more than expected to reach $1.2 ...

Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what its prospects are for the next ...

This pushed Lilly to raise its sales outlook for the year by $2 billion, despite short revenue from diabetes treatments Mounjaro and Trulicity. Analysts noted Eli Lilly and its biggest rival ...

For years, Eli Lilly's business has relied heavily on top-selling diabetes drug Trulicity for growth. But with the approval of Mounjaro for diabetes and Zepbound for weight loss, it's a much ...

The one clear blemish for LLY was the 31% drop in Trulicity revenue to $1.25 bln. Rising competition, including from its own Mounjaro diabetes drug, is hurting demand for Trulicity. However, that's a ...

The data from two Phase III trials demonstrated GLP-1/glucagon agonist’s efficacy in reducing blood glucose and weight.

Since 1972, shares of Eli Lilly have generated a total return north of 100,000%. Clearly, Lilly has been a consistent ...

Eli Lilly’s crop of new products propelled the ... for the firm was likely the resilience of its diabetes blockbuster Trulicity. Trulicity (dulaglutide) grew more than expected to reach $1.2 ...